Menu
GeneBe

YARS2

tyrosyl-tRNA synthetase 2, the group of Aminoacyl tRNA synthetases, Class I

Basic information

Region (hg38): 12:32727489-32755897

Links

ENSG00000139131NCBI:51067OMIM:610957HGNC:24249Uniprot:Q9Y2Z4AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • myopathy, lactic acidosis, and sideroblastic anemia 2 (Definitive), mode of inheritance: AR
  • myopathy, lactic acidosis, and sideroblastic anemia 2 (Strong), mode of inheritance: AR
  • myopathy, lactic acidosis, and sideroblastic anemia (Supportive), mode of inheritance: AR
  • myopathy, lactic acidosis, and sideroblastic anemia 2 (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Myopathy, lactic acidosis, and sideroblastic anemia 2ARCardiovascular; HematologicIndividuals may develop transfusion-dependent sideroblastic anemia in infancy; Surveillance for cardiovascular manifestations may allow early medical interventionsCardiovascular; Hematologic; Musculoskeletal20598274; 22504945; 24344687; 24430573

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the YARS2 gene.

  • not provided (190 variants)
  • Myopathy, lactic acidosis, and sideroblastic anemia 2 (48 variants)
  • Hereditary Sideroblastic Anemia with Myopathy and Lactic Acidosis (26 variants)
  • Inborn genetic diseases (19 variants)
  • Myopathy, lactic acidosis, and sideroblastic anemia (18 variants)
  • not specified (14 variants)
  • Lethal Encephalopathy (11 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the YARS2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
42
clinvar
1
clinvar
45
missense
1
clinvar
9
clinvar
79
clinvar
3
clinvar
92
nonsense
4
clinvar
1
clinvar
1
clinvar
6
start loss
0
frameshift
7
clinvar
2
clinvar
1
clinvar
10
inframe indel
1
clinvar
4
clinvar
5
splice donor/acceptor (+/-2bp)
0
splice region
2
3
5
non coding
6
clinvar
22
clinvar
8
clinvar
36
Total 12 13 93 67 9

Highest pathogenic variant AF is 0.000230

Variants in YARS2

This is a list of pathogenic ClinVar variants found in the YARS2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
12-32730955-A-G Likely benign (Jun 14, 2018)678892
12-32730998-C-T not specified Benign (Jan 30, 2024)260164
12-32731003-T-C Likely benign (Oct 03, 2023)1664307
12-32731007-C-T Likely benign (Jun 29, 2021)1569267
12-32731017-C-T not specified Likely benign (Dec 30, 2023)508840
12-32731018-G-A Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 • DNM1L-related disorder Pathogenic (Dec 01, 2023)253262
12-32731019-G-A Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 Likely pathogenic (Jan 01, 2015)253261
12-32731021-G-A Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 Likely pathogenic (Feb 19, 2021)976414
12-32731022-G-A Mitochondrial disease Likely pathogenic (Oct 08, 2021)1299486
12-32731022-G-T Uncertain significance (Oct 04, 2022)2000000
12-32731025-C-A Likely pathogenic (Apr 01, 2019)806859
12-32731033-T-C Likely pathogenic (Apr 01, 2020)1066546
12-32731038-T-C Likely benign (Dec 09, 2023)2801329
12-32731042-T-C Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 Likely pathogenic (May 28, 2019)802833
12-32731058-G-C Uncertain significance (Jan 13, 2020)1311010
12-32731061-G-A Uncertain significance (Dec 27, 2022)3018814
12-32731069-G-A Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 Likely pathogenic (Jun 23, 2014)374321
12-32731075-G-A Uncertain significance (Jul 19, 2022)1355014
12-32731076-T-C Inborn genetic diseases Uncertain significance (Dec 22, 2023)1356396
12-32731084-C-T Uncertain significance (Sep 10, 2023)3019814
12-32731118-C-A Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 Pathogenic (Oct 15, 2010)6015
12-32731124-G-C Uncertain significance (Dec 17, 2021)2045594
12-32731127-A-G Uncertain significance (Jan 02, 2024)2090349
12-32731142-T-C Likely benign (Sep 20, 2021)1604532
12-32731143-G-A not specified • DNM1L-related disorder Benign/Likely benign (Jan 06, 2024)214302

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
YARS2protein_codingprotein_codingENST00000324868 528413
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
3.00e-110.15512532714201257480.00168
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.2642472590.9540.00001303074
Missense in Polyphen6272.1490.85934874
Synonymous-0.9661211081.120.000005521013
Loss of Function0.6291821.10.8520.00000126205

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.01440.0144
Ashkenazi Jewish0.000.00
East Asian0.0003330.000326
Finnish0.002960.00296
European (Non-Finnish)0.0006180.000615
Middle Eastern0.0003330.000326
South Asian0.0002610.000261
Other0.0004900.000489

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr- AMP and then transferred to the acceptor end of tRNA(Tyr). {ECO:0000269|PubMed:15779907, ECO:0000269|PubMed:17997975}.;
Disease
DISEASE: Myopathy with lactic acidosis and sideroblastic anemia 2 (MLASA2) [MIM:613561]: A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia. {ECO:0000269|PubMed:20598274, ECO:0000269|PubMed:22504945}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Aminoacyl-tRNA biosynthesis - Homo sapiens (human);tRNA Aminoacylation;Translation;Metabolism of proteins;Tyrosine metabolism;tRNA charging;Mitochondrial tRNA aminoacylation (Consensus)

Recessive Scores

pRec
0.285

Intolerance Scores

loftool
0.846
rvis_EVS
-0.47
rvis_percentile_EVS
23.43

Haploinsufficiency Scores

pHI
0.109
hipred
N
hipred_score
0.317
ghis
0.587

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
E
essential_gene_gene_trap
E
gene_indispensability_pred
E
gene_indispensability_score
0.992

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Yars2
Phenotype

Gene ontology

Biological process
translation;tRNA aminoacylation for protein translation;tRNA aminoacylation;mitochondrial tyrosyl-tRNA aminoacylation
Cellular component
mitochondrion;mitochondrial matrix;cytosol;nuclear body
Molecular function
tRNA binding;RNA binding;tyrosine-tRNA ligase activity;protein binding;ATP binding;protein homodimerization activity;tyrosine binding